🚀 VC round data is live in beta, check it out!
Oryzon Genomics Valuation Multiples
Discover revenue and EBITDA valuation multiples for Oryzon Genomics and similar public comparables like Adagene, Reig Jofré, S Biomedics, Binex and more.
Oryzon Genomics Overview
About Oryzon Genomics
Oryzon Genomics SA is a clinical stage biopharmaceutical company and engaged in the development of epigenetics-based therapeutics. It is engaged in the field of epigenetic medicine and in the development of therapeutic, biological solutions for cancer and neurodegenerative diseases.
Founded
2000
HQ
Employees
40
Website
Financials (LTM)
EV
$239M
Oryzon Genomics Financials
Oryzon Genomics reported last 12-month revenue of $2M and negative EBITDA of ($10M).
In the same LTM period, Oryzon Genomics generated $2M in gross profit, ($10M) in EBITDA losses, and had net loss of ($6M).
Revenue (LTM)
Oryzon Genomics P&L
In the most recent fiscal year, Oryzon Genomics reported revenue of — and EBITDA of ($6M).
Oryzon Genomics expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $2M | XXX | — | XXX | XXX | XXX |
| Gross Profit | $2M | XXX | $13M | XXX | XXX | XXX |
| Gross Margin | 83% | XXX | — | XXX | XXX | XXX |
| EBITDA | ($10M) | XXX | ($6M) | XXX | XXX | XXX |
| EBITDA Margin | (500%) | XXX | — | XXX | XXX | XXX |
| EBIT Margin | (524%) | XXX | — | XXX | XXX | XXX |
| Net Profit | ($6M) | XXX | ($3M) | XXX | XXX | XXX |
| Net Margin | (292%) | XXX | — | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Oryzon Genomics Stock Performance
Oryzon Genomics has current market cap of $263M, and enterprise value of $239M.
Market Cap Evolution
Oryzon Genomics' stock price is $3.39.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $239M | $263M | 0.3% | XXX | XXX | XXX | $-0.04 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialOryzon Genomics Valuation Multiples
Oryzon Genomics trades at 121.0x EV/Revenue multiple, and (24.2x) EV/EBITDA.
EV / Revenue (LTM)
Oryzon Genomics Financial Valuation Multiples
As of April 18, 2026, Oryzon Genomics has market cap of $263M and EV of $239M.
Equity research analysts estimate Oryzon Genomics' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Oryzon Genomics has a P/E ratio of (45.6x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $263M | XXX | $263M | XXX | XXX | XXX |
| EV (current) | $239M | XXX | $239M | XXX | XXX | XXX |
| EV/Revenue | 121.0x | XXX | — | XXX | XXX | XXX |
| EV/EBITDA | (24.2x) | XXX | (41.7x) | XXX | XXX | XXX |
| EV/EBIT | (23.1x) | XXX | (35.5x) | XXX | XXX | XXX |
| EV/Gross Profit | 145.9x | XXX | 19.0x | XXX | XXX | XXX |
| P/E | (45.6x) | XXX | (85.7x) | XXX | XXX | XXX |
| EV/FCF | (22.4x) | XXX | (24.1x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Oryzon Genomics Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Oryzon Genomics Margins & Growth Rates
Oryzon Genomics' revenue in the last 12 month grew by 445%.
Oryzon Genomics' revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $0.5M for the same period.
Oryzon Genomics Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 445% | XXX | — | XXX | XXX | XXX |
| EBITDA Margin | (500%) | XXX | — | XXX | XXX | XXX |
| EBITDA Growth | (9%) | XXX | 90% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.5M | XXX | XXX | XXX |
| G&A Expenses to Revenue | 290% | XXX | — | XXX | XXX | XXX |
| R&D Expenses to Revenue | 725% | XXX | — | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Oryzon Genomics Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Oryzon Genomics | XXX | XXX | XXX | XXX | XXX | XXX |
| Adagene | XXX | XXX | XXX | XXX | XXX | XXX |
| Reig Jofré | XXX | XXX | XXX | XXX | XXX | XXX |
| S Biomedics | XXX | XXX | XXX | XXX | XXX | XXX |
| Binex | XXX | XXX | XXX | XXX | XXX | XXX |
| Compugen | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Oryzon Genomics M&A Activity
Oryzon Genomics acquired XXX companies to date.
Last acquisition by Oryzon Genomics was on XXXXXXXX, XXXXX. Oryzon Genomics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Oryzon Genomics
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialOryzon Genomics Investment Activity
Oryzon Genomics invested in XXX companies to date.
Oryzon Genomics made its latest investment on XXXXXXXX, XXXXX. Oryzon Genomics invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Oryzon Genomics
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Oryzon Genomics
| When was Oryzon Genomics founded? | Oryzon Genomics was founded in 2000. |
| Where is Oryzon Genomics headquartered? | Oryzon Genomics is headquartered in Spain. |
| How many employees does Oryzon Genomics have? | As of today, Oryzon Genomics has over 40 employees. |
| Is Oryzon Genomics publicly listed? | Yes, Oryzon Genomics is a public company listed on Bolsa de Madrid. |
| What is the stock symbol of Oryzon Genomics? | Oryzon Genomics trades under ORY ticker. |
| When did Oryzon Genomics go public? | Oryzon Genomics went public in 2015. |
| Who are competitors of Oryzon Genomics? | Oryzon Genomics main competitors are Adagene, Reig Jofré, S Biomedics, Binex. |
| What is the current market cap of Oryzon Genomics? | Oryzon Genomics' current market cap is $263M. |
| What is the current revenue of Oryzon Genomics? | Oryzon Genomics' last 12 months revenue is $2M. |
| What is the current revenue growth of Oryzon Genomics? | Oryzon Genomics revenue growth (NTM/LTM) is 445%. |
| What is the current EV/Revenue multiple of Oryzon Genomics? | Current revenue multiple of Oryzon Genomics is 121.0x. |
| Is Oryzon Genomics profitable? | No, Oryzon Genomics is not profitable. |
| What is the current EBITDA of Oryzon Genomics? | Oryzon Genomics has negative EBITDA and is not profitable. |
| What is Oryzon Genomics' EBITDA margin? | Oryzon Genomics' last 12 months EBITDA margin is (500%). |
| What is the current EV/EBITDA multiple of Oryzon Genomics? | Current EBITDA multiple of Oryzon Genomics is (24.2x). |
| What is the current FCF of Oryzon Genomics? | Oryzon Genomics' last 12 months FCF is ($11M). |
| What is Oryzon Genomics' FCF margin? | Oryzon Genomics' last 12 months FCF margin is (541%). |
| What is the current EV/FCF multiple of Oryzon Genomics? | Current FCF multiple of Oryzon Genomics is (22.4x). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.